How AI is increasing objectivity in mental health research

Facial analysis enabled by AI is helping researchers assess mental health in a more objective way, relying on algorithms that detect behavioral biomarkers rather than subjective exams alone, the Wall Street Journal reported April 1.

Louis-Philippe Morency, an associate professor of computer science at Carnegie Mellon University in Pittsburgh, is one of the scientists working on the case. He and colleagues at Carnegie Mellon and the University of Southern California have established more than a dozen behavioral biomarkers for conditions like depression, post-traumatic stress disorder, schizophrenia and suicide.

“We built a dictionary of these behavior markers for different mental health disorders,” Morency told the Wall Street Journal. “The technology gives you a summary of these behavior markers and we can use it as part of a treatment to see how that person is behaving today compared to a month ago.”

Other researchers at Columbia and the University of Pittsburgh are in the midst of a clinical trial that’s testing whether smartphones can detect some of those biomarkers in adolescents. Between 200 and 300 teens are expected to take part in the six-month trial.

When taught to recognize certain markers—depressed people don’t enunciate their vowels as much, for example, and suicidal patients who talk in a breathy tone are more likely to re-attempt suicide than if they’re talking in a tense voice—the smartphones might be able to provide some objective data to contribute to patients’ ultimate diagnoses. The tech is meant to act as a supplementary tool to a traditional doctor’s assessment.

“This doesn’t mean if you suddenly have a breathy voice, you are suicidal,” Morency said. “This is one sign that the doctor should be able to use as they are doing their assessment.”

Read more below:

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.